ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclin...(included in this press releasethat are n...)

Date:10/25/2007

included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical data suggests or as otherwise anticipated; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones, including funding the continued development of ANX-514; the FDA's views on the appropriateness of seeking marketing approval of ANX-514 under Section 505(b)(2); difficulties or delays in developing, testing, manufacturing and marketing and obtaining regulatory approval for ANX-514, including receiving necessary regulatory approvals for clinical trials of ANX-514, in a timely manner or at all, and the potential for automatic injunctions regarding FDA approval of ANX-514 and other challenges by patent holders during the Section 505(b)(2) process; uncertainty under Section 505(b)(2) resulting from legal action against the FDA and the potential that future interpretations of Section 505(b)(2) could delay or prevent the FDA from approving any Section 505(b)(2) NDA; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; patent and non-patent exclusivity covering docetaxel; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at ht
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
2. Sensient reduces debt, must pay settlement
3. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
4. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
5. Detection of Morphine and Morphine-Glucuronide in Saliva or Urine with a Rapid and Simple Method Without Derivatization on the Varian 500-MS
6. DHC 2007: Without fuller IT adoption, health costs might drain Americas wealth
7. Wisconsin wont get Georgia biotech without a fight
8. Some Madisonians content without city wireless
9. Researchers report development of embryonic stem cells without destroying embryo
10. Succeeding online without a Web site
11. Encrypted data without the fuss